Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline)

MELVIN D. YAHR, MARINA R. MENDOZA, DANIEL MOROS, KENNETH J. BERGMANN

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

ABSTRACT — There are at present numerous pharmacological agents available for the control of parkinson symptoms. None are ideal; all have their limitations. The most potent is levodopa administered with a peripheral decarboxylase inhibitor. However, because its effectiveness declines after long‐term use and side effects increase in severity, it should be reserved for individuals with established symptoms which are functionally impairing. In patients with minimal symptoms, anticholinergic agents, or agents which facilitate dopaminergic mechanisms normally operative in the nervous system, should be used. In a limited trial, deprenyl has produced promising results during this phase of parkinsonism. Deprenyl's major usefulness however, has been demonstrated in patients under treatment with levodopa which has become complicated by fluctuating responses – particularly those of the end‐start‐dose variety. In such patients, it is possible to achieve an increase in “on” time and a decrease in the severity of parkinsonism. In most patients, such a response can maintained for a period of two years or longer. 1983 Blackwell Munksgaard

Original languageEnglish
Pages (from-to)95-102
Number of pages8
JournalActa Neurologica Scandinavica
Volume68
DOIs
StatePublished - Jul 1983
Externally publishedYes

Keywords

  • Parkinson's disease
  • deprenyl (selegiline) indication
  • mechanisms and means of control
  • plan of treatment in various phases
  • use of cholinergic and dopaminergic agents
  • “on‐off” phenomena types

Fingerprint

Dive into the research topics of 'Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline)'. Together they form a unique fingerprint.

Cite this